drugset / Trial / NCT01042314

Drug-Drug Interaction Study With Aricept® (Donepezil)

NCT01042314

Phase 1 Completed 18 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to find out if the plasma concentration of donepezil is changed when BMS-708163 is administered at the same time

Timeline

Start
2010-01
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Avagacestat Small molecule 125 mg Oral
Subject Donepezil Small molecule 5 mg Oral

Indications